RxDoctor Payments Data

Richard Schloss, MD

Psychiatry · Huntington, NYNPI 1992856660

Payments from drug & device makers

$22,143in general payments, 2019–2025

Across 869 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Alkermes, Inc.$2K
  • plus $9K from 29 others

What the payments were for

  • Food & beverage$22,00099%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,143 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$149,356
Medicare patients
165
Services billed
1,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine11$114,547
VraylarCariprazine Hcl16$43,961
XanaxAlprazolam14$25,695
Lurasidone Hcl31$15,572
Aripiprazole130$13,934
BelsomraSuvorexant23$9,795
Quetiapine Fumarate99$5,736
Bupropion XlBupropion Hcl133$4,321
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine113$4,307
Clonazepam328$2,827
Clomipramine Hcl27$2,482
Mirtazapine124$2,453
Duloxetine Hcl96$2,404
Escitalopram Oxalate157$2,348
Modafinil18$2,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$2,312$114,54711 claims
AbbVieVraylar$2,745$43,96116 claims
MerckBelsomra$185$9,79523 claims
Almatica Pharma LLCSertraline Hcl$189$1,411128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Huntington

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →